Minapharm Pharmaceuticals (CAI:MIPH) Other Stockholders Equity: E£4,512 Mil (As of Dec. 2025)


CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£698.08
GF Value E£362.31
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Other Stockholders Equity?

Minapharm Pharmaceuticals CAI:MIPH -0.27% 41 Other Stockholders Equity is E£4,512 Mil as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Minapharm Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Dec. 2025 was E£4,512 Mil.

Minapharm Pharmaceuticals's quarterly Other Stockholders Equity increased from Jun. 2025 (E£2,611 Mil) to Sep. 2025 (E£3,956 Mil) and increased from Sep. 2025 (E£3,956 Mil) to Dec. 2025 (E£4,512 Mil).

Minapharm Pharmaceuticals's annual Other Stockholders Equity increased from Dec. 2023 (E£1,526 Mil) to Dec. 2024 (E£2,439 Mil) and increased from Dec. 2024 (E£2,439 Mil) to Dec. 2025 (E£4,512 Mil).

Minapharm Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Other Stockholders Equity Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
597.10 1,186.66 1,526.10 2,439.06 4,512.10

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,439.06 2,595.59 2,611.44 3,955.70 4,512.10
CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of E£4,512 Mil mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Other Stockholders Equity of E£4,512 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Minapharm Pharmaceuticals and its competitors.
Is Minapharm Pharmaceuticals' Other Stockholders Equity too high?
Minapharm Pharmaceuticals' current Other Stockholders Equity is E£4,512 Mil. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Other Stockholders Equity compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Other Stockholders Equity of E£4,512 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Other Stockholders Equity is E£4,512 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current Other Stockholders Equity is E£4,512 Mil. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Other Stockholders Equity is E£4,512 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Other Stockholders Equity: E£4,512 Mil
  • GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
  • GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£698.08
Price
E£362.31
GF Value